Skip to content

West Pharmaceutical Services

US · WST #752 by market cap Listed 1970
390.30 -6.39 -1.61%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions decreased by 1 in the most recent period (2026/Q4).
  • Total institutional ownership rose 0.2 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
101.49% +0.20pp
Institutions
1,076 -1
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund84.75%
Public Company4.69%
Hedge Fund2.95%
Private Company2.56%
Government Pension Fund2.40%
Sovereign Wealth Fund1.31%
Corporate Pension Plan0.80%
VC/PE Fund0.67%
Foundation0.64%

Top holders as of 2026-09-30

BlackRock 9.62% · 6.70M sh
FMR 8.27% · 5.76M sh
Vanguard Capital Management, LLC 7.18% · 5.00M sh
Vanguard Portfolio Management, LLC 5.93% · 4.13M sh
State Street Global Advisors 4.78% · 3.33M sh
Artisan Partners Limited Partnership 2.88% · 2.01M sh
Geode Capital Management, LLC 2.78% · 1.94M sh
T. Rowe Price Group, Inc. 2.57% · 1.79M sh
Generation Investment Management LLP 2.91% · 2.03M sh
UBS Asset Management 1.71% · 1.19M sh
Eaton Vance Management 1.62% · 1.13M sh
BNY Mellon Asset Management 2.50% · 1.74M sh
Walter Scott & Partners Limited 1.86% · 1.31M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 37 buys · 12 sells

NameRoleStake
Eric Green Former Non-Independent Chair of the Board, President & CEO 0.26%
Douglas Michels Independent Director 0.07%
Thomas Hofmann Former Independent Director 0.06%
Mark Buthman Independent Director 0.06%
William Feehery Independent Director 0.05%
Annette Favorite Chief HR Officer & Senior VP 0.03%
Myla Lai-Goldman Independent Director 0.02%
Paolo Pucci Independent Director 0.02%
Deborah L. Tanner -- 0.02%
Michel Lagarde Chief Executive Officer 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-29 Janet Haugen Independent Director Other Derivative Acquisition +44 --
2026-09-14 Annette Favorite Chief HR Officer & Senior VP Derivative Exercise and Sale -7,524 $89.64–365.00
2026-09-07 Michel Lagarde Chief Executive Officer Other Derivative Acquisition +14,750 --
2026-09-07 Michel Lagarde Chief Executive Officer Other Derivative Acquisition +37,048 $337.75
2026-09-07 Annette Favorite Chief HR Officer & Senior VP Derivative Exercise and Sale -8,135 $83.47–340.81
2026-08-30 Michel Lagarde Chief Executive Officer Initial Statement of Beneficial 0 --
2026-08-10 Robert McMahon Senior Vice President Derivative Exercise and Sale -3,109 $351.37
2026-08-10 Robert McMahon Senior Vice President Derivative Exercise and Retained +4,040 --
2026-06-29 Janet Haugen Independent Director Other Derivative Acquisition +46 --
2026-05-11 Shane Campbell SVP & Chief Proprietary Segment Officer Derivative Exercise and Sale -219 $312.07
2026-05-11 Shane Campbell SVP & Chief Proprietary Segment Officer Derivative Exercise and Retained +550 --
2026-05-06 Thomas Hofmann Former Independent Director Intent to Sell (Form 144) -3,384 $322.12
2026-05-03 Myla Lai-Goldman Independent Director Other Acquisition +791 --
2026-05-03 Robert Friel Independent Chairperson Other Acquisition +791 --
2026-05-03 Janet Haugen Independent Director Other Acquisition +791 --
2026-05-03 Mark Buthman Independent Director Other Acquisition +791 --
2026-05-03 Douglas Michels Independent Director Other Acquisition +791 --
2026-05-03 Deborah L. Tanner -- Other Acquisition +791 --
2026-05-03 Paolo Pucci Independent Director Other Acquisition +791 --
2026-05-03 Stephen Lockhart Independent Director Other Acquisition +791 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

West Pharmaceutical Services discussion 0 comments

Add a comment